Canine Lyme Disease Vaccine

Immunogenic compositions using alphavirus RNA replicon particles encoding OspA and OspC antigens in dogs enhance Lyme disease protection by inducing effective borreliacidal antibodies, addressing genetic diversity and extending vaccine efficacy.

JP7825939B2Active Publication Date: 2026-03-09INTERVET INT BV
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2020530359
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2017-12-04
Filing Date
2018-12-03
Publication Date
2026-03-09
Estimated Expiration
2038-12-03

AI Technical Summary

Technical Problem

Existing Lyme disease vaccines for dogs provide limited and short-term protection due to genetic diversity among Borrelia species and the heterogeneity of OspC proteins, leading to ineffective borreliacidal antibody responses.

Method used

Development of immunogenic compositions using alphavirus RNA replicon particles encoding Borrelia burgdorferi antigens, particularly OspA and OspC, to induce comprehensive and long-lasting borreliacidal antibodies, combined with potential inclusion of non-Borrelial immunogens for broader protection.

Benefits of technology

The vaccines significantly enhance protection against Lyme disease by inducing both opsonizing IgG and borreliacidal antibodies, providing extended efficacy and reducing adverse reactions, while also offering protection against other canine pathogens.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007825939000001
    Figure 0007825939000001
  • Figure 0007825939000002
    Figure 0007825939000002
  • Figure 0007825939000003
    Figure 0007825939000003
Patent Text Reader

Abstract

The present invention provides a vaccine for canine Lyme disease and methods for preparing or using the vaccine alone or in combination with other protective agents.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Use of the Borrelia cidal epitope of the Borrelia burgdorferi outer surface protein c (ospc) as a vaccine.

    JP2002523019A

  • Compositions and methods using the borreliacidal epitope(s) of borrelia burgdorferi outer surface protein C (OspC) for the diagnosis and prevention of lyme disease

    US6210676B1

  • Compositions and methods using the borreliacidal epitope(s) of Borrelia burgdorferi outer surface protein C (OspC) for the diagnosis and prevention of lyme disease

    US6464985B1

  • Immunogenic formulation of OspC antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens

    US6872550B1

  • Canine lyme disease vaccine

    US8137678B2